synthetic peptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-11-12. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
=== Venom extraction syringes === Venom extraction syringes are different from standard syringes, because they usually do not puncture the wound. The most common types have a plastic nozzle which is placed over the affected area, and then the syringe piston is pulled back, creating a vacuum that allegedly sucks out the venom. Attempts to treat snakebites in this way are specifically advised against, as they are ineffective and can cause additional injury. Syringes of this type are sometimes used for extracting human botfly larvae from the skin.
In 1993, True came in contact with the Tarahumara or Rarámuri runners from Chihuahua, Mexico. In 1994, he began spending his winters running in the Copper Canyons, where he built a hut and began establishing a relationship with the Tarahumara natives.
On 18 December 2008, at the Old Bailey, Napper pleaded guilty to the manslaughter of Rachel Nickell on the grounds of diminished responsibility. Mr Justice Griffith Williams said that Napper would be detained indefinitely at Broadmoor because he was "a very dangerous man".
Sources: en.wikipedia.org
The term "percent homology" is often used to mean "sequence similarity", that is the percentage of identical residues (percent identity), or the percentage of residues conserved with similar physicochemical properties (percent similarity), e.g. leucine and isoleucine, is usually used to "quantify the homology." Based on the definition of homology specified above this terminology is incorrect since sequence similarity is the observation, homology is the conclusion. The term "percent homology" is a misnomer; sequences are either homologous or not. As with morphological and anatomical structures, sequence similarity might occur because of convergent evolution, or, as with shorter sequences, by chance, meaning that they are not homologous. Homologous sequence regions are also called conserved. This is not to be confused with conservation in amino acid sequences, where the amino acid at a specific position has been substituted with a different one that has functionally equivalent physicochemical properties. Partial homology can occur where a segment of the compared sequences has a shared origin, while the rest does not. Such partial homology may result from a gene fusion event.
27 March – A report clears Conservative MP Bernard Jenkin of breaching COVID-19 laws over his attendance at a "wine and nibbles" event on the Parliamentary estate in December 2020, which the report describes as socially-distanced with "business and social elements". 28 March – Keir Starmer and Angela Rayner launch Labour's campaign for the 2024 United Kingdom local elections at an event in Dudley. Honours are conferred on businessman and senior Conservative Party treasurer Mohamed Mansour, Farming Minister Mark Spencer and Shipley MP Philip Davies, all of who receive knighthoods, while former ministers Tracey Crouch and Harriett Baldwin are awarded damehoods. The announcement comes as part of an honours list published at the start of the Parliamentary recess. The Assisted Dying for Terminally Ill Adults (Scotland) Bill, a bill to legalise assisted dying in Scotland and drafted by Liberal Democrat MSP Liam McArthur, is introduced into the Scottish Parliament. 29 March – Sir Jeffrey Donaldson resigns as leader of the Democratic Unionist Party after being charged with rape and other historical sexual offences. Gavin Robinson is appointed interim leader until a new leader can be elected. 30 March – First Minister of Northern Ireland Michelle O'Neill says she is determined the Stormont Assembly and Executive will continue to function following the resignation of Jeffrey Donaldson as DUP leader. 31 March – The UK government says it will work alongside the Northern Ireland Executive to maintain stability at Stormont.
Medications – chemotherapy, sulfas or other antibiotics, phenothiazines, benzodiazepines, antithyroid medications, anticonvulsants, quinine, quinidine, indometacin, procainamide, thiazides Radiation Toxins – alcohol, benzenes Intrinsic disorders – Fanconi's, Kostmann's, cyclic neutropenia, Chédiak–Higashi Immune dysfunction – connective tissue diseases, AIDS, rheumatoid arthritis Blood cell dysfunction – megaloblastic anemia, myelodysplasia, Bone marrow failure, Bone marrow transplant, acute leukemia Any major infection Miscellaneous – starvation, hypersplenism Symptoms of neutropenia are associated with the underlying cause of the decrease in neutrophils. For example, the most common cause of acquired neutropenia is drug-induced, so an individual may have symptoms of medication overdose or toxicity. Treatment is also aimed at the underlying cause of the neutropenia. One severe consequence of neutropenia is that it can increase the risk of infection.
A few bacteria have chemical systems that generate light. This bioluminescence often occurs in bacteria that live in association with fish, and the light probably serves to attract fish or other large animals. Bacteria often function as multicellular aggregates known as biofilms, exchanging a variety of molecular signals for intercell communication and engaging in coordinated multicellular behaviour. The communal benefits of multicellular cooperation include a cellular division of labour, accessing resources that cannot effectively be used by single cells, collectively defending against antagonists, and optimising population survival by differentiating into distinct cell types. For example, bacteria in biofilms can have more than five hundred times the increased resistance to antibacterial agents than individual "planktonic" bacteria of the same species. One type of intercellular communication by a molecular signal is called quorum sensing. Quorum sensing determines whether the local population is dense enough to support investment in processes that are only successful if large numbers of similar organisms behave similarly, such as excreting digestive enzymes or emitting light. Quorum sensing enables bacteria to coordinate gene expression and to produce, release, and detect autoinducers or pheromones that accumulate with the growth in cell population.
Sources: en.wikipedia.org
The COVID-19 Immunity Task Force (CITF) was one of the Government of Canada's early efforts to track the 2020 coronavirus pandemic. An external, dedicated secretariat was established in order to maximize the efficiency of the CITF's work. The group terminated its mandate on March 31, 2024. The group terminated its mandate on March 31, 2024. During the four-year period, the CITF provided several purposes and uses for the general Canadian population. The CITF was to use a serology "to survey representative samples of the population for the presence of antibodies to the virus". Trudeau's press release on 23 April 2020, on the initiation of the CCITF listed several goals it would help to achieve notably that it would: establish priorities and oversee the coordination of a series of country-wide blood test surveys that will tell us how widely the virus has spread in Canada and provide reliable estimates of potential immunity and vulnerabilities in Canadian populations. Canada's government funded more than $1 billion for research into how to combat COVID-19 through the CITF.
Seaborg, a scientist at Lawrence Berkeley National Laboratory who had been involved in work to make such superheavy elements, had said in December 1997 that "one of his longest-lasting and most cherished dreams was to see one of these magic elements"; he was told of the synthesis of flerovium by his colleague Albert Ghiorso soon after its publication in 1999. Ghiorso later recalled:
Speckionian Genio (スペキオン星人ジェニオ, Supekion Seijin Jenio): A mirror-themed criminal from Planet Speckion who possesses the ability to travel through and trap people in reflective surfaces and is charged with trapping over 1,000,000 people on 124 planets in his mirror world as his personal "works of art" and murdering Tetsu's parents after they inadvertently surprised him during an attempt to escape S.P.D. on Earth. Two years prior to the series, he was captured by Tetsu and eventually incarcerated in Prison Satellite Alcapo (監獄衛星アルカポ, Kangoku Eisei Arukapo) in solitary confinement and denied access to reflective surfaces. Despite this, Genio would become famous among other Alienizers and inspire criminals to outdo or impress him. In the present, Tetsu questions Genio about a rash of copycat crimes, with the latter revealing the culprit is Bolapeno in exchange for whether Tetsu remembered what his mother said at the time of her death to make him cry. Using Tetsu's tear, Genio escapes and returns to Earth to make Tetsu suffer further. However, Tetsu discovers how to free Genio's victims before deleting him. During the events of the crossover film Tokusou Sentai Dekaranger vs. Abaranger, Saunaginnan resurrects Genio, but the latter is deleted by Deka Blue, Green, and Break and Abare Blue. Genio is voiced by Keiichi Noda (野田 圭一, Noda Keiichi). Karakazian Don Sanoa (カラカズ星人ドンサノーア, Karakazu Seijin Sanōa): A shark-themed mass-murderer from Planet Karakaz and the head of the Space Mafia Zundaz Family (宇宙マフィア・ズンダーズファミリー, Uchū Mafia Zundāzu Famirī).
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.